PEACE-1, 2022 NCT01957436
abiraterone plus docetaxel plus ADT (n=355) vs. docetaxel plus ADT (n=355)
randomized controlled trial
abiraterone androgen deprivation therapy with docetaxel population
androgen deprivation therapy with docetaxel population
metastatic, hormone-sensitive prostate cancer